Acceleron Pharma Inc. (NASDAQ:XLRN) headquartered in Cambridge, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 5:00 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.acceleronpharma.com
Earnings Expectation
Acceleron Pharma Inc. is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, XLRN is expected to report 3Q20 loss of $ 0.61 per share from revenue of $ 26.27 million.
For the full year, analysts anticipate top line of $ 98.14 million, while looking forward to loss of $ 2.49 per share bottom line.
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension.
